Clinical trial
An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
NCT00699283 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
- Lead sponsor
- UCB Pharma
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2008
- Completion date
- March 31, 2010
- Enrollment
- 62 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.